Literature DB >> 30196109

Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.

Jin-Bo Zhu1, Shen Xu2, Jun Li1, Jin Song1, Biao Luo3, Ya-Ping Song3, Zhi-Hui Zhang1, Yuan-Hua Chen4, Dong-Dong Xie1, De-Xin Yu5, De-Xiang Xu6.   

Abstract

It is increasingly recognized that farnesoid X receptor (FXR) has anti-inflammatory and antioxidant activities. The present study investigated the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, on renal inflammation and oxidative stress in a model of sepsis-induced acute kidney injury. All mice except controls were intraperitoneally injected with lipopolysaccharide (LPS, 2.0 mg/kg). In the OCA + LPS group, mice were orally pretreated with three doses of OCA (5 mg/kg) at 48, 24 and 1 h before LPS injection. Interestingly, OCA pretreatment alleviated LPS-induced renal dysfunction and pathological damage. Moreover, OCA pretreatment repressed renal inflammatory cytokines and chemokines during LPS-induced acute kidney injury. In addition, OCA blocked nuclear translocation of nuclear factor kappa B (NF-κB) p65 and p50 subunits in tubular epithelial cells of renal cortex. Additional experiment showed that OCA pretreatment attenuated LPS-induced renal glutathione depletion, lipid peroxidation and protein nitration. Moreover, OCA pretreatment inhibited the upregulation of renal NADPH oxidase and inos genes during LPS-induced acute kidney injury. In conclusion, OCA pretreatment protects against sepsis-induced acute kidney injury through inhibiting renal inflammation and oxidative stress. These results provide evidence for roles of FXR as an important regulator of inflammation and oxidative stress in the kidney.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Acute kidney injury; FXR; Inflammation; OCA; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30196109     DOI: 10.1016/j.ejphar.2018.09.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Bile acids and salt-sensitive hypertension: a role of the gut-liver axis.

Authors:  Jeanne A Ishimwe; Thanvi Dola; Lale A Ertuglu; Annet Kirabo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-04       Impact factor: 4.733

2.  Investigating the Mechanisms of Jieduquyuziyin Prescription Improves Lupus Nephritis and Fibrosis via FXR in MRL/lpr Mice.

Authors:  Jingqun Liu; Qing Ma; Qice Sun; Qihan Luo; Yiheng Wang; Cheng Wang; Akao Zhu; Lisha Zhao; Lu Yin; Jiang Lou; Yu Dong; Ping Qiu
Journal:  Oxid Med Cell Longev       Date:  2022-07-09       Impact factor: 7.310

Review 3.  Nuclear receptors in the kidney during health and disease.

Authors:  Andrew E Libby; Bryce Jones; Isabel Lopez-Santiago; Emma Rowland; Moshe Levi
Journal:  Mol Aspects Med       Date:  2020-11-30

4.  Pretreatment with Cholecalciferol Alleviates Renal Cellular Stress Response during Ischemia/Reperfusion-Induced Acute Kidney Injury.

Authors:  Jun Li; Shen Xu; Jin-Bo Zhu; Jin Song; Biao Luo; Ya-Ping Song; Zhi-Hui Zhang; Yuan-Hua Chen; Zhi-Qiang Zhang; Dong-Dong Xie; De-Xin Yu; De-Xiang Xu
Journal:  Oxid Med Cell Longev       Date:  2019-03-25       Impact factor: 6.543

Review 5.  Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

Authors:  Yoshio Sumida; Masashi Yoneda; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Hideki Hayashi; Yoichi Nishigaki; Yusuke Suzuki; Takafumi Naiki; Asahiro Morishita; Hiroshi Tobita; Shuichi Sato; Naoto Kawabe; Shinya Fukunishi; Tadashi Ikegami; Takaomi Kessoku; Yuji Ogawa; Yasushi Honda; Takashi Nakahara; Kensuke Munekage; Tsunehiro Ochi; Koji Sawada; Atsushi Takahashi; Taeang Arai; Tomomi Kogiso; Satoshi Kimoto; Kengo Tomita; Kazuo Notsumata; Michihiro Nonaka; Kazuhito Kawata; Taro Takami; Takashi Kumada; Eiichi Tomita; Takeshi Okanoue; Atsushi Nakajima
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  Obeticholic acid attenuates human immunodeficiency virus/alcohol metabolism-induced pro-fibrotic activation in liver cells.

Authors:  Moses New-Aaron; Murali Ganesan; Raghubendra Singh Dagur; Kusum K Kharbanda; Larisa Y Poluektova; Natalia A Osna
Journal:  World J Hepatol       Date:  2020-11-27

Review 7.  Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review.

Authors:  Anna Pia Delli Bovi; Francesca Marciano; Claudia Mandato; Maria Anna Siano; Marcella Savoia; Pietro Vajro
Journal:  Front Med (Lausanne)       Date:  2021-02-26

Review 8.  The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity.

Authors:  Kemp M Anderson; Christopher P Gayer
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

9.  Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice.

Authors:  Wei Chen; Xing-Xing Gao; Li Ma; Zhi-Bing Liu; Li Li; Hua Wang; Lan Gao; De-Xiang Xu; Yuan-Hua Chen
Journal:  Oxid Med Cell Longev       Date:  2019-11-15       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.